Impact of ICCAN on Cancer Treatment Completion and Quality of Life
A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life
1 other identifier
observational
347
1 country
11
Brief Summary
The purpose of this study is to see if the ICCAN program is working, and to compare the ICCAN program to the standard hospital services provided in New York City hospitals, like meeting with a Social Worker or a Patient Navigator (a person who provides personal hospital guidance).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2012
Longer than P75 for all trials
11 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2012
CompletedFirst Submitted
Initial submission to the registry
December 3, 2012
CompletedFirst Posted
Study publicly available on registry
December 5, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 1, 2027
April 28, 2026
April 1, 2026
15 years
December 3, 2012
April 23, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Treatment completion/adherence
The primary outcome, cancer treatment completion, will be determined by chart review at 3, 6, and 12 months after enrollment.
1 year
Secondary Outcomes (1)
Quality of life
1 year
Study Arms (3)
Phase I: Refinement
10 Black, Hispanic, and/or low-SES patients with TNBC (5 Spanish-speaking), will be recruited from MSK
Phase II, Arm 1: Usual and Customary Care (U&C)
Participants in this group will receive the same referrals on social and economic resources as ICCAN group.
Phase II, Arm 2: ICCAN-IO
Arm 2 will consist of everything in Arm 1
Interventions
Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year. Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance.
Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year. Chart review at 3 mo, 6 mo and 1 year, and as needed.
Eligibility Criteria
Eligible cancer patients will be recruited in person by multilingual ICCAN Clinical Research Coordinators for participation in the study at Ralph Lauren Center for Cancer Care and Prevention (RLCCP), Lincoln Hospital (LH) and Lutheran Medical Center (LMC). In the event that MSK staff is not present when an eligible patient is identified. Refinement and Pilot RCT participants will be recruited through MSK Manhattan and OneMSK regional sites's.
You may qualify if:
- Patient is eligible if he/she is
- fluent in English, Spanish, or Mandarin
- between the ages of 21-80 years old
- cancer patients currently receiving chemotherapy (started within the past month) and/or radiation therapy (started within the past week), or
- scheduled to begin chemotherapy and/or radiation therapy within the next 2 months (excluding surgery only patients)
- planning on remaining in the area for at least 1 year
- Clinician is eligible if he/she:
- Has an MD or DO degree
- Is the treating physician providing care to a patient enrolled to the study
- ICCAN-IO Phase 1: Refinement, participant is eligible if he/she per EMR or self-report:
- Is 18 - 85 years of age
- Has unresectable locally advanced, locally recurrent unresectable, metastatic, or high risk/early stage TNBC or stage I-IV lung cancer
- Eligible for FDA approved immunotherapy in the NYC metropolitan area (per self-report or per MSK patient EMR records).
- Is treated in the NY metropolitan area
- Self-identifies as Black or Hispanic, and/or is low-SES (low SES will be defined as household income \< 200% of federal poverty level)
- +12 more criteria
You may not qualify if:
- Patient is ineligible is he/she is:
- Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent
- ICCAN-IO Phase 1: Refinement, participant is ineligible if he/she per EMR or self-report:
- Presence of untreated psychiatric disturbance (e.g., acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
- Participants or family members who are participating in MSK IHCD studies related to social determinants of health
- ICCAN-IO Phase 2: Pilot RCT, participant is ineligible if he/she per EMR or self-report:
- Presence of untreated psychiatric disturbance (e.g, acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) sufficient to preclude completion of the assessment measures, interview or informed consent
- Participants or family members who are participating in MSK IHCD studies related to social determinants of health
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Memorial Sloan Kettering Cancer Centerlead
- National Cancer Institute (NCI)collaborator
- The City College of New Yorkcollaborator
- Ralph Lauren Center for Cancer Care and Preventioncollaborator
- Lincoln Medical and Mental Health Centercollaborator
- Lutheran Medical Centercollaborator
Study Sites (11)
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey, 07645, United States
Lutheran Medical Center
Brooklyn, New York, 11220, United States
Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities)
Commack, New York, 11725, United States
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison, New York, 10604, United States
City College of New York (Data Collection AND Data Analysis)
New York, New York, 10031, United States
Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities)
New York, New York, 10035, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Rockville Centre, New York, 11553, United States
Lincoln Hospital and Mental Health Center
The Bronx, New York, United States
Related Publications (1)
Gany F, Melnic I, Li Y, Finik J, Wu M, Ramirez J, Hwang C, Leng J, Blinder V. A Randomized Controlled Trial of the Integrated Cancer Care Access Network on Cancer Treatment Completion and Quality of Life. J Natl Compr Canc Netw. 2025 Jun 10;23(7):e257017. doi: 10.6004/jnccn.2025.7017.
PMID: 40494401DERIVED
Related Links
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Francesca Gany, MD, MS
Memorial Sloan Kettering Cancer Center
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 3, 2012
First Posted
December 5, 2012
Study Start
November 1, 2012
Primary Completion (Estimated)
November 1, 2027
Study Completion (Estimated)
November 1, 2027
Last Updated
April 28, 2026
Record last verified: 2026-04